New malaria vaccine shows promise in early human trial
NCT ID NCT06735209
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than earlier vaccines. Researchers will check if it is safe, well-tolerated, and whether it can prevent infection when volunteers are later exposed to malaria under controlled conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PfSPZ-LARC2 vaccine (genetically weakened malaria parasites)
What this could lead to
If successful, this could lead to a more effective malaria vaccine that provides stronger and longer-lasting protection than current options.
What could go wrong
This is a very early Phase 1 trial with only 22 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Washington - Virology Research Clinic
Seattle, Washington, 98104, United States